Table of Content

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Personalized Medicine in Oncology dealmaking

2.1. Introduction
2.2. Personalized Medicine in Oncology partnering over the years
2.3. Most active Personalized Medicine in Oncology dealmakers
2.4. Personalized Medicine in Oncology partnering by deal type
2.5. Personalized Medicine in Oncology partnering by therapy area
2.6. Deal terms for Personalized Medicine in Oncology partnering
2.6.1 Personalized Medicine in Oncology partnering headline values
2.6.2 Personalized Medicine in Oncology deal upfront payments
2.6.3 Personalized Medicine in Oncology deal milestone payments
2.6.4 Personalized Medicine in Oncology royalty rates

Chapter 3 – Leading Personalized Medicine in Oncology deals

3.1. Introduction
3.2. Top Personalized Medicine in Oncology deals by value

Chapter 4 – Most active Personalized Medicine in Oncology dealmakers

4.1. Introduction
4.2. Most active Personalized Medicine in Oncology dealmakers
4.3. Most active Personalized Medicine in Oncology partnering company profiles

Chapter 5 – Personalized Medicine in Oncology contracts dealmaking directory

5.1. Introduction
5.2. Personalized Medicine in Oncology contracts dealmaking directory

Chapter 6 – Personalized Medicine in Oncology dealmaking by technology type

Biomarkers
Companion diagnostics
Personalised medicine
Pharmacogenomics

Chapter 7 – Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 – Personalized Medicine in Oncology deals by company A-Z

Appendix 2 – Personalized Medicine in Oncology deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed

Appendix 3 – Personalized Medicine in Oncology deals by deal type

Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Spin out
Sub-license
Supply
Technology transfer

Appendix 4 – Personalized Medicine in Oncology deals by therapy area

Bladder cancer
Bone cancer
Brain cancer
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial
Esophageal cancer
Gastric cancer
Head and neck cancer
Kidney cancer
Leukemia
Acute lymphoblastic leukemia
Acute myelogenous leukemia
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
Liver cancer
Lung cancer
Non small cell lung cancer
Lymphoma
Non Hodgkin’s lymphoma
Melanoma
Mesothelioma
Metastases
Multiple myeloma
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal cell carcinoma
Sarcoma
Solid tumors
Symptoms
Oral mucositis
Testicular cancer
Thyroid cancer

Appendix 5 –Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Personalized Medicine in Oncology partnering since 2014
Figure 2: Active Personalized Medicine in Oncology dealmaking activity– 2014 to 2019
Figure 3: Personalized Medicine in Oncology partnering by deal type since 2014
Figure 4: Personalized Medicine in Oncology partnering by disease type since 2014
Figure 5: Personalized Medicine in Oncology deals with a headline value
Figure 6: Personalized Medicine in Oncology deals with an upfront value
Figure 7: Personalized Medicine in Oncology deals with a milestone value
Figure 8: Personalized Medicine in Oncology deals with a royalty rate value
Figure 9: Top Personalized Medicine in Oncology deals by value since 2014
Figure 10: Most active Personalized Medicine in Oncology dealmakers 2014 to 2019
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events